Post-remission therapy for patients not proceeding to HSCT

During the AML Hub Steering Committee meeting, held in November 2023, key opinion leaders met to discuss postremission therapy for patients not proceeding to hematopoietic stem cell transplantation. This recorded session was chaired by Gail Roboz and featured Charles Craddock, Gert Ossenkoppele, Gunnar Juliusson, Jefferey Lancet, Jorge Sierra, Roland Walter, and Yasushi Miyazaki.

The steering committee discussed current induction strategies, how to optimize remission rates, and the impact of measurable residual disease on treatment decisions. They also considered how various global centers manage patients with NPM1-mutated acute myeloid leukemia in first morphological measurable residual disease-negative remission by polymerase chain reaction who are eligible for transplantation.